Protein with human choriogonadotropin inhibitory effect

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C436S065000, C436S814000, C436S818000

Reexamination Certificate

active

06448022

ABSTRACT:

This invention relates to a decidual inhibitory protein (DIP) having an inhibitory effect on the production of human choriogonadotropin (hCG). More particularly, this invention relates to a protein isolated from human decidual cells with a preliminary amino acid analysis and a molecular weight of about 7,000 to about 10,000 daltons (as measured by ultrafiltration and gel chromatography) which may be used to inhibit hCG production in vivo (to induce abortion) or in vitro, measured in vivo or in vitro to diagnose the cause of hCG inhibition as an indication of potential miscarriage, or used in the treatment of hCG-secreting tumors.
BACKGROUND
The fetoplacental unit plays an essential role in the complicated hormonal interplay that is necessary for a successful pregnancy. Human choriogonadotropin (hCG), a hormone secreted by the trophoblast cells of the placenta, is present in the blood and urine during pregnancy. The primitive trophoblast begins producing hCG soon after fertilization and concentrations of hCG rise to peak values at 8-12 weeks of pregnancy, then decrease to a plateau level that is maintained during the remainder of the pregnancy. hCG may also be produced by certain trophoblastic or ectopic neoplasms.
Following fertilization, hCG stimulates the sustained secretion of progesterone by the corpus luteum, which is necessary for the growth of the uterine endometrium. hCG also is a stimulus for the production of fetal testicular androgens.
Decreased production of hCG can result in spontaneous abortion. Many abnormal pregnancies are associated with decreased levels of hCG as compared to normal pregnancies of the same duration. Most of these pregnancies end in spontaneous abortions. (B. Saxena, in
Endocrinology of Pregnancy
, Fuchs et al. Eds, Harper & Row, Philadelphia (1983) pp. 50-72).
The decidualized endometrium of the uterus also produces substances necessary for gestation. The decidualized endometrium and the placental trophoblast are contiguous tissues, and prior studies have investigated the possibility that each may influence the function of the other. Studies performed over a decade ago showed that hCG secretion from placental explants rose over the initial 72 hour period, leading researchers to suggest that loss of an endogenous hCG inhibitory factor (lost as it was removed from culture during changes of growth media) was responsible. (A. Golander et al.,
Endocrinology
102:597-605 (1978)). Yuen and coworkers have suggested that prolactin released by the decidua inhibits hCG production by trophoblasts. (B. H. Yuen, et al.
Am. J. Obstet. Gynecol
. 154:336-340 (1986)). Conversely, trophoblast hCG secretion has been found to be stimulated by interleukin-l produced by placental phagocytic cells and decidual cells. (A. Flynn, et al.,
Science
, 218:475-476 (1982) and S. Yagel et al.,
J. Clin. Endocrinol. Metab
., 68:992-995 (1989)).
Recently, Vicovac and Genvacev provided evidence, through co-incubation of trophoblasts and decidual cells, that the decidua has an inhibitory effect on the synthesis of hCG and total protein by trophoblast cells. (L. J. Vicovac et al.,
Placenta
9:109-115, (1988)). They concluded that some endometrial secretory product or products act to inhibit total protein synthesis and hCG secretion and/or synthesis by the trophoblast tissue.
Characterization of an endometrial hCG inhibitor was heretofore unknown. Potential uses for such a substance include as an agent to induce therapeutic abortions, as a basis to develop methods of evaluating hCG inhibition in vivo, or as a treatment of hCG-secreting tumors. The present inventors noted the inhibitory effect of a substance produced by decidual cells, and searched for the active material. As a result, the present inventors have found that a protein of a preliminary amino acid analysis and a molecular weight of about 7,000 to about 10,000 daltons (as measured by ultrafiltration and gel chromatography) is produced by the decidua and has an inhibitory effect on hCG production by the trophoblast and by JEG-3 choriocarcinoma cells.
SUMMARY OF THE INVENTION
The present invention is directed to a composition of matter which inhibits hCG production by human trophoblast cells and JEG-3 choriocarcinoma cells. The present invention is also directed to a method for inhibiting hCG release comprising contacting hCG producing tissue with an effective amount of the composition of the invention. The present invention is also directed to methods of evaluating hCG inhibition in vivo and in vitro, comprising quantifying the amount of the composition of the invention produced in vivo or in vitro.
The protein of the present invention may also be of use in the treatment of hCG-secreting tumors. Since the placental trophoblast is the normal site of synthesis of hCG, it is understandable that both gestational and nongestational trophoblastic tumors synthesize and secrete hCG. Indeed, hCG measurements have been quite useful for the diagnosis of these tumors, staging the tumors, and for monitoring the effects of therapy. In addition, some nontrophoblastic tumors may produce hCG ectopically. hCG may act as a growth factor for some tumors (Melmed S. and Braunstein GD: Human chorionic gonadotropin stimulates proliferation of Nb 2 rat lymphoma cells.
J. Clin. Endocrinol. Metab
56:1068-1070, (1983)). Therefore, the use of a material which suppresses the production of hCG may suppress the growth of an hCG-secreting tumor. This has been previously shown with the use of anti-hCG antibodies in animal tumor models.
The present composition comprises a substantially-pure polypeptide of a preliminary amino acid analysis and a molecular weight of about 7,000 to about 10,000 daltons (as measured by ultrafiltration and gel chromatography), wherein said polypeptide inhibits the production of hCG by human trophoblast and JEG-3 choriocarcinoma cells. This polypeptide can be isolated from cultures of human decidual cells by cultivation and centrifugation of the culture medium. As used herein, “substantially pure” is intended to mean that DIP has been isolated from the decidual cells.


REFERENCES:
patent: 4558035 (1985-12-01), Johnson
patent: 4912201 (1990-03-01), Dizerega
patent: 5140100 (1992-08-01), Braunstein et al.
Kato et al, “Discordant Secretion of Placental Protein Hormones . . . ”J. Clin. Endo. Met. 8(4): 814-820 (Apr. 1989).*
Yagel et al. “Interleukin-1 Stimulates Human Chorionic Gonadotropin . . . ”J. Clin. Endo. Met. 68(5): 992-995 (May 1989).*
Clinical Research, vol. 38, No. 1, Jan. 1990, p. 148A, Thorofare, New Jersey, USA, Ren et al. “A Decidual Protein Inhibits Choriogonadotropin Release From Human Trophoblasts”.
Clinical Research, vol. 38, No. 2, Apr. 1990, p. 298A, Thorofare, New Jersey, USA, Ren et al. “The Decidua Produces A Protein That Inhibits Choriogonadotropin Release From Human Trophoblasts”.
Placenta, vol. 9, No. 2, 1998, pp. 109-115, Eastbourne, England, Vicovac et al., “Coincubation-An Experimental Approach To The Study of Decidual-Trophoblast Interaction”.
The Journal of Clinical Investigation, vol. 876, No. 1, pp. 326-330, Jan. 1991, New York, USA Ren et al., “Decidua Produces A Protein That Inhibits Choriogonadotrophin Release From Human Trophoblasts”.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Protein with human choriogonadotropin inhibitory effect does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Protein with human choriogonadotropin inhibitory effect, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein with human choriogonadotropin inhibitory effect will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2864663

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.